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Abstract 
Background: Diabetic neuropathy is one of the most common complications of diabetes and causes various prob‑
lems in daily life. The aim of this study was to assess the effect of regional anaesthesia on post surgery opioid induced 
hyperalgesia in diabetic and non‑diabetic mice.
Methods: Diabetic and non‑diabetic mice underwent plantar surgery. Levobupivacaine and sufentanil were used 
before surgery, for sciatic nerve block (regional anaesthesia) and analgesia, respectively. Diabetic and non‑diabetic 
groups were each randomly assigned to three subgroups: control, no sufentanil and no levobupivacaine; sufentanil 
and no levobupivacaine; sufentanil and levobupivacaine. Three tests were used to assess pain behaviour: mechanical 
nociception; thermal nociception and guarding behaviours using a pain scale.
Results: Sufentanil, alone or in combination with levobupivacaine, produced antinociceptive effects shortly after 
administration. Subsequently, sufentanil induced hyperalgesia in diabetic and non‑diabetic mice. Opioid‑induced 
hyperalgesia was enhanced in diabetic mice. Levobupivacaine associated to sufentanil completely prevented hyperal‑
gesia in both groups of mice.
Conclusion: The results suggest that regional anaesthesia can decrease opioid‑induced hyperalgesia in diabetic as 
well as in non‑diabetic mice. These observations may be clinically relevant for the management of diabetic patients.
Keywords: Diabetes, Levobupivacaine, Naloxone, Opioid induced hyperalgesia, Pain, Plantar incision, Regional 
anaesthesia, Sufentanil
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Background
Diabetes affected approximately 387 million people 
worldwide in 2014 (International Diabetes Federation, 
http://www.idf.org/diabetesatlas); by 2035 these numbers 
are projected to rise up 592 million people [1–3]. Neu-
ropathy, defined as hypersensitivity to noxious stimuli, 
is a common complication of diabetes which appears 
in about 60% of the diabetic patients [4, 5]. Since relief 
of pain in diabetic patients improves the functional and 
health status outcomes [6], treatment of painful diabetic 
neuropathy is essential. Anaesthetic and analgesic man-
agement of these patients is still challenging for anaesthe-
siologists [7].
Perioperative pain is a risk factor for developing 
chronic pain after surgery. Exogenous opioids provide 
analgesia to acute pain; however, opioid-induced hyper-
algesia (OIH) may subsequently occur with a paradoxi-
cal increase in pain after opioid administration. OIH 
has been clearly evidenced in patients after surgery, in 
particular when exposed to high doses of the widely 
perioperatively used selective μ opioid receptor agonist 
remifentanil [6, 8, 9].
Diabetic patients have additional risks in surgery, 
with more instable cardiovascular control under anaes-
thesia [10] and loss of myocardial preconditioning of 
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remifentanil [11]. Moreover, sustained analgesic action 
can be altered in diabetic patients [6]. Recently, periph-
eral nerve block has become a popular anaesthetic option 
in the perioperative management of patients with dia-
betes mellitus (types 1 and 2) [12]. Regional anaesthesia 
(RA) provides better postoperative analgesia than does 
general anaesthesia, while avoiding the cardiopulmonary 
and insulin-resistance effects of general anaesthesia [7].
Rodent models of diabetes (induced by streptozocin 
injection) develop peripheral neuropathy and slower 
conduction times in both sensory and motor nerves (by 
5 weeks) [13, 14]. These changes in peripheral nerves may 
affect the onset of a local anaesthetic block, and even the 
susceptibility to nerve toxicity of local anaesthetics [7, 15]. 
Recently, it has been shown that the perioperative use of 
regional anaesthesia reduced postoperative hyperalgesia 
and inflammation in rats [16]. OIH has been first evi-
denced in animal models [17, 18]. Remifentanil induced 
pro-nociceptive effects in a model of plantar incision pain 
in mice [19]. Rodent models are currently used to study 
underlying mechanisms and new therapeutics. The aim of 
the present study was to evaluate the impact of regional 
anaesthesia (levobupivacaine sciatic block) on postop-
erative (plantar surgery) sufentanil induced hyperalgesia 
in diabetic and non-diabetic mice, focusing primarily on 
hyperalgesia and secondarily on wound healing.
Methods
Animals
Mice were housed in a pathogen-free facility and handled 
in accordance with the procedures outlined in the Coun-
cil Directive 86/609/EEC. The investigation conformed 
to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institute of Health (NIH 
publication No. 85-23, revised 1996). Experimental pro-
cedures were conducted according to the official edict 
presented by the French Ministry of Agriculture (Paris, 
France) and the recommendations of the Helsinki Dec-
laration. The French Animal Care and Use Committee 
of the Toulouse University approved these experiments. 
Male 10–12  week-old C57BL/6J mice (Janvier, France) 
weighing 22.7–25.0  g were used. After arrival, animals 
were allowed to recover for 1 week in groups of six ani-
mals in plexiglas cages. During the whole experiment, 
mice were housed at 21°C under a controlled 12 h light 
dark cycle and received water and food ad libitum. At end 
point, mice were killed with compressed carbon dioxide 
and the paws were removed and rapidly processed for 
histological analysis.
Induction of diabetes
Streptozotocin (STZ)-treated mice were used as a model 
of type 1 diabetes [20]. Diabetes was induced by three 
consecutive intraperitoneal injections of STZ (Sigma-
Aldrich, St-Quentin-Fallavier, France), at a daily dose of 
80 µg/g body weight in 100 µl of sterile 0.05 M sodium 
citrate (pH 4.5). The non-diabetic control group received 
an equal volume of sodium citrate vehicle. Glycaemia was 
assessed using an Accu-chek glucometer (Roche, Paris, 
France) on blood from the tail vein. Mice with blood glu-
cose level above 400 mg/dl were considered diabetic and 
included in the experiments. Experiments started 41 days 
after the last STZ injection to allow development of dia-
betic neuropathy [14].
Surgery
The procedure for plantar incision has been described in 
previous report from Brennan’s team [21]. Briefly, placing 
the animals in a plastic box that contained 4% sevoflu-
rane in air induced anaesthesia. The depth of anaesthesia 
was assessed using withdrawal reflex of the left paw (the 
forelimb pedal withdrawal response after a hard pinched 
toe was absent). Anaesthesia was maintained by admin-
istrating 3–4% sevoflurane in air via a conenose. Ani-
mals received or not levobupivacaine before the incision 
as described below in the experimental groups section. 
After antiseptic preparation of the right hind paw with 
povidone iodine, a deep 8-mm longitudinal incision was 
made with a number 11 blade through the skin, fascia, 
and (plantar flexor digitorum brevis) muscle of the right 
hind paw [22]. The skin was closed with two single 6-0 
nylon sutures, and the wound site was covered with povi-
done iodine. After surgery, anaesthesia was discontinued, 
and the animals were allowed to recover in their cage.
Sciatic nerve block and criteria for nerve block assessment
Regional anaesthesia (RA) of the sciatic nerve was per-
formed as follows. The sciatic nerve was identified using 
a nerve stimulator settled at 0.2 mA and 1 Hz (B-Braun, 
Melsungen, Germany) via a 22  G-diameter needle [23]. 
After localization of the sciatic nerve just posterior of 
the great trochanter, each animal received a single 0.1 ml 
injection of 5% levobupivacaine (Chirocaïne, Abbott, 
Rungis, France) in the sciatic nerve area. Efficacy of 
the RA was assessed by the loss of motor control in the 
injected limb according to the scores: 0 (normal move-
ment); 1 (unable to flex the limb completely); and 2 (total 
paralysis) [23]. Any animal unable to walk normally 
with the injected limb was considered to have a posi-
tive response to RA. Efficacy of the motor blockade was 
evaluated every 5 min up to the end of the sciatic nerve 
blockade. Ten diabetic mice were compared with ten 
non-diabetic mice. These tested mice were not included 
in the following experimental groups. To evaluate RA in 
mice of the experimental groups, only mice with efficient 
block (total paralysis) were included.
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Experimental groups
Non-diabetic and diabetic mice were randomly assigned 
each to three different groups (groups 1–3 and groups 
4–6, respectively) with 10 mice per group: control 
(groups 1 and 4: no OIH, no sciatic block, plantar inci-
sion), OIH (groups 2 and 5: OIH, no sciatic block, plantar 
incision), and OIH +  RA (groups 3 and 6: OIH, sciatic 
block, plantar incision). We studied the early and long-
lasting effects of sufentanil on nociceptive threshold 
using a procedure designed to partly mimic its use in sur-
gery. More precisely, in the C control groups (1 and 4); 
saline was subcutaneously injected four times at 15-min 
intervals. Surgery was performed as described above 
after the last injection. In the S groups (2, and 5), sufen-
tanil was injected four times at 15-min intervals (10 µg/
kg per subcutaneous injection), resulting in total doses of 
40 µg/kg [24]. Surgery was performed as described above 
after the last injection. In the S + RA groups (3 and 6), 
sufentanil was injected four times (10 µg/kg per injection, 
subcutaneously) at 15-min intervals, resulting in total 
doses of 40  µg/kg. [24] Sciatic blockade was performed 
before the last sufentanil injection. Plantar surgery was 
performed as described above after the last injection. 
Pain testing (mechanical stimulation, hot plate test, and 
guarding behaviors) was performed before the surgery 
(D-1 and D0: basal B) and post surgery (30 min, 2, 4 and 
6  h after surgery, once daily until D7, and at D14). In 
addition, to unmask OIH, for all groups of mice on day 
D7, a single subcutaneous injection of the non selective 
opioid antagonist naloxone (naloxone hydrochloride, 
Sigma) was performed (1 mg/kg in 0.9% NaCl) [25] and 
the mice were tested for mechanical stimulation and hot 
plate before and 30 min after naloxone injection (BN, AN 
time points, respectively).
Behavioral tests
Mechanical nociception (allodynia) was quantified by 
measuring the hind paw withdrawal response to von 
Frey filament stimulation. Unrestrained mice were 
placed beneath a clear plastic chamber on an elevated 
mesh floor and were allowed to acclimate. Withdrawal 
responses to mechanical stimulation were determined 
using calibrated von Frey filaments applied from under-
neath the cage through the mesh floor to the hindpaw 
plantar skin adjacent but avoiding the wound. The fila-
ment was pushed until it slightly bowed and was main-
tained in that position for 6  s. Each von Frey filament 
was applied once, starting from least (0.008  g) to great-
est forces until a withdrawal response was reached which 
was considered a positive response [26]. The entire test 
was repeated three times. The lowest positive force from 
the three tests was considered as the withdrawal thresh-
old (data expressed in g) [27, 28].
Thermal nociception was assessed by the withdrawal 
response to thermal stimulus using a modified hot-plate 
test [24, 29]. The time to hind paw withdrawal from a 
52°C hot plate (thermal withdrawal latency) was meas-
ured. The paw was removed from the plate by the inves-
tigator after a maximal 12 s time to avoid thermal injury 
and thermal hyperalgesia [27–29].
Guarding behaviours (non-evoked pain behaviours) 
were assessed using a cumulative pain score as described 
by Banik and Brennan [30]. Unrestrained mice were 
placed beneath a clear plastic chamber on an elevated 
mesh floor and were allowed to acclimate. Animals 
were habituated to the testing scenario by two testings. 
Testings were all performed in the same cage in a quiet 
room and by the same experimenter who was blinded 
with respect to the treatment groups. Both paws of each 
animal were closely observed during a 1-min period 
repeated every 5 min for 1 h. Depending on the position 
in which each paw was found during the majority of the 
1 min scoring period, a 0, 1, or 2 was given. Full weight 
bearing of the paw (score = 0) was present if the wound 
was blanched or distorted by the mesh. If the paw was 
completely off the mesh, a score of 2 was recorded. If the 
area of the wound touched the mesh without blanching 
or distortion, a 1 was given. The sum of the 12 scores 
(0–24) during the 1 h session was obtained for each paw. 
The difference between the scores from the incised paw 
and non-incised paw was the cumulative pain score for 
that 1 h period.
Histopathological examination of skin incision and wound 
healing
The histological examination of skin incision and wound 
healing of mice was performed for three mice in each 
group of diabetic and non-diabetic mice, at day 1 (D1), 
D7 and D14. Paw specimens were fixed in formalin and 
embedded in paraffin. Decalcification was performed if 
necessary. Sections of 4 µm thickness were stained with 
hematoxylin and eosin. To assess the effect of RA on 
wound healing, histological examination was performed 
at D14 in the diabetic and non-diabetic mice. The pathol-
ogist was blinded for the experimental group.
A pathologist experienced in this field who was blinded 
to the animal’s group, using light microscopy at 10× and 
40× magnifications by randomly sampling the prepa-
ration, conducted the histopathological examination. 
Inflammation infiltration was analysed by four-grade 
semi quantitative scoring: 0, no inflammation, 1, weak, 2 
moderate, 3 strong.
Statistical analysis
Data are expressed as mean ± SD. The values of behav-
ioural testing were not normally distributed and thus 
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were analysed non-parametrically. To assess whether 
the withdrawal responses changed over time, Friedman’s 
test was used. When Friedman’s test was significant 
(P  <  0.05), pairwise comparisons were performed using 
Wilcoxon’s signed rank test. Time points comparisons 
between groups were performed using first a non-par-
ametric Kruskal–Wallis test; when Kruskal–Wallis test 
was significant (P  <  0.05), pairwise comparisons were 
performed using the Mann–Whitney U test.
Results
Induction of diabetes in mice
Fifty mice with initial mean body weight of 25.5 ± 3.0 g 
were treated with three consecutive STZ i.p injections. 
Twelve days after the injections, 10 of the 50 STZ-treated 
mice did not develop diabetes, as indicated by sub-
normal glycemia or mild hyperglycemia (<400  mg/dl); 
these animals were excluded from the following experi-
ments. Mean parameters for the diabetic mice were gly-
cemia 520  ±  80  mg/dl, hematocrit 48.3  ±  2.6%, mean 
body weight 23.4  ±  3.2  g. Experiments started 41  days 
after STZ treatment, with thirty STZ-treated stably dia-
betic well-walking mice (glycemia 610  ±  130  mg/dl, 
hematocrit 47.9 ± 2.2%, mean body weight 26.4 ± 2.9 g) 
and thirty vehicle-treated non diabetic mice (glycemia 
133  ±  41  mg/dl, hematocrit 49.9  ±  2.1%, mean body 
weight 28.7 ± 2.3 g).
Effect of diabetes on duration of sciatic nerve blockade 
in mice
The duration of the sciatic nerve blockade (regional 
anaesthesia, RA) was significantly longer in the diabetic 
mice as compared to the non-diabetic mice (Figure 1).
Effect of regional anaesthesia on opioid induced 
hyperalgesia in non‑diabetic mice
No differences in the measured parameters were 
observed between the non-diabetic groups before 
experiments (D-1) (Figure 2). At D0 shortly after admin-
istration (H ½), sufentanil produced antinociceptive 
effects with modifications of the responses to mechani-
cal and thermal stimulations, and of the subjective pain 
scale (Figure  2). And then sufentanil induced hyperal-
gesia (OIH) from D0-H4 to D3, as regards mechanical 
nociception, thermal nociception and guarding score 
(p < 0.05 between the H2-D3, H2-D2, D3-D5 points of 
the S and C curves in Figure 2a–c, respectively). At D0, 
the sufentanil and RA association produced antinocice-
ptive effects shortly after administration (H ½), similarly 
to sufentanil alone (Figure  2). RA associated to sufen-
tanil prevented the D0-H4 to D3 OIH, when compared 
to the sufentanil group (Figure 2). The pain parameters 
were even improved in the S  +  RA group compared 
to the control C group (P  <  0.05 between the H2–
H6 points of the S +  RA and C curves in Figure  2a–c 
respectively). The results suggest that RA prevented 
OIH in non diabetic mice.
Effect of regional anaesthesia on opioid induced 
hyperalgesia in diabetic mice
No differences in the measured parameters were 
observed between the diabetic groups before experi-
ments (D-1) (Figure  3). However, basal withdrawal 
thresholds (D-1) and latency were slightly reduced, 
when compared to parameters of the non-diabetic 
mice at D-1 (Figure 2a, b) (P < 0.05). As for the non-
diabetic mice, at D0, sufentanil produced antinoci-
ceptive effects shortly after its administration (H ½) 
with modification of the responses to mechanical and 
thermal stimulation, as well as the subjective pain 
scale (Figure  3). Then sufentanil induced hyperalge-
sia (OIH) from D0-H4 to D3 as regards mechanical 
nociception, thermal nociception and guarding score 
(P  <  0.05 between the H4-D3, H2-D3, D2–D4 points 
of the S and C curves in Figure  3a–c, respectively) 
reaching lower nociceptive threshold values than in 
non-diabetic mice (Compare Figure 3 to Figure 2). At 
D0, sufentanil and RA association produced antino-
ciceptive effects shortly after administration (H ½), 
similarly to sufentanil alone (Figure 3). Then RA asso-
ciated to sufentanil prevented the D0-H4 to D3 OIH 
when compared to the sufentanil group (Figure 3). The 
parameters were even improved in the S + RA group 
compared to the control C group (P  <  0.05 between 
the H4–H6, H2–H6, H2-D3 points of the S + RA and 
C curves, Figure  3a–c respectively). The results sug-
gest that RA prevented OIH in diabetic mice.
Figure 1 Effect of diabetes on the duration of regional anaesthesia 
in mice. The duration of a sciatic nerve block with levobupivacaine 
was evaluated in non‑diabetic and diabetic mice. The duration of loss 
of motor control (min) was recorded for each animal. Min minutes, 
ND non‑diabetic mice, D diabetic mice, n = 10 per group. *P < 0.05.
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Figure 2 Effect of regional anaesthesia on opioid induced hyper‑
algesia in non‑diabetic mice. The actions of levobupivacaine sciatic 
nerve block on perioperative sufentanil induced hyperalgesia were 
evaluated by three behavioural tests: a time course of mechanical 
allodynia (withdrawal threshold to von Frey filament, in g), results 
expressed as mean ± SD; b time course of heat hyperalgesia (with‑
drawal latency on hot plate, in s), results expressed as mean ± SD; c 
guarding pain behaviour (0–24 cumulative pain score). Non‑diabetic 
control group 1 (C): no sufentanil, no levobupivacaine sciatic block, 
plantar incision; non‑diabetic OIH group 2 (S): sufentanil, no levobupi‑
vacaine sciatic block, plantar incision; non‑diabetic OIH + RA group 
3 (S + RA): sufentanil, levobupivacaine sciatic block, plantar incision. 
Naloxone injection was performed for all groups on D7. *P < 0.05 
compared group 2 to group 1 (control); +P<0.05 compared group 3 
to group 1. AN after naloxone, BN before naloxone, B basal, C control, 
D day, H hour, g gram, PI plantar incision, RA regional anaesthesia, S 
sufentanil, s second.
Figure 3 Effect of regional anaesthesia on opioid induced hyperal‑
gesia in diabetic mice. The actions of levobupivacaine sciatic nerve 
block on perioperative sufentanil induced hyperalgesia were evalu‑
ated by three behavioural tests: a von frey; b hot plate; c guarding 
pain behaviour. Diabetic control group 4 (C): no sufentanil, no lev‑
obupivacaine sciatic block, plantar incision; diabetic OIH group 5 (S): 
sufentanil, no levobupivacaine sciatic block, plantar incision; diabetic 
OIH + RA group 6 (S + RA): sufentanil, levobupivacaine sciatic block, 
plantar incision. *P < 0.05 compared group 5 to group 4 (control); 
+P<0.05 compared group 6 to group 4. AN after naloxone, BN before 
naloxone, B basal, C control, D day, H hour, g gram, PI plantar incision, 
RA regional anaesthesia, S sufentanil, s second. Data presented as 
mean ± SD.
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Effect of regional anaesthesia on histopathological 
examination of skin incision and wound healing
Histology of mice paws
Histology of hind paws is shown in Figure  4. Wound 
healing occurred in non-diabetic mice paws between D1 
and D14 (compare Figure 4a–c) whereas persistent acute 
inflammatory cells with delayed wound healing were 
observed in diabetic mice paws at D14 (Figure 4e–g). RA 
did not alter healing in non-diabetic mice at D14 (Fig-
ure  4d) whereas it reduced inflammation and improved 
wound healing in diabetic mice paws (Figure 4h).
Regional anaesthesia influences wound inflammation
Effect of RA on wound infiltration is shown in Figure 5. 
Inflammation infiltration diminished from D1 to D14 in 
non-diabetic mice. No difference was found at D14 con-
cerning the wound inflammation between non-diabetic 
with or without regional anaesthesia. No significant 
difference was found from D1 to D7 in diabetic mice. 
Inflammation infiltration diminished from D7 to D14 in 
diabetic mice. Inflammation infiltration was diminished 
in diabetic mice at D14 when regional anaesthesia was 
performed. No difference was found at D1 concerning 
the wound inflammation between non-diabetic and dia-
betic mice. But, at D7 and D14 inflammation infiltration 
was higher in diabetic mice when compared to non-
diabetic mice. However, when regional anaesthesia was 
performed no difference was found between diabetic and 
non-diabetic mice at D14.
Discussion
Results from this study provide the first evidence that 
regional anaesthesia (RA) prevented OIH in diabetic as 
well as in non-diabetic animals. We used an STZ-induced 
model of diabetes and found that RA reduced the exag-
gerated postoperative pain exacerbated by hyperalgesia 
in diabetic mice. Importantly, RA completely prevented 
sufentanil-induced hyperalgesia (OIH) in non-diabetic 
mice as well as in diabetic mice.
The experimental STZ-induced diabetic rodent model 
is commonly used to investigate diabetic pain [14, 31–
33]. In the present study, we used STZ mice with sta-
bly established hyperglycemia (5  weeks); in accordance 
with previous reports, polydipsia and reduced weight 
occurred after STZ administration. In addition, the mice 
developed diabetes-induced neuropathy with persistent 
hyperalgesia (reduced von Frey withdrawal response at 
D-1), as described in previous reports [31] [34–36].
Local anaesthesia was performed through sciatic nerve 
blockade with levobupivacaine. We observed increased 
duration of the sciatic block in the diabetic mice. This 
first report in diabetic mice is consistent with previous 
findings in rats [12, 37, 38].
Opioid-induced hyperalgesia (paradoxical opioid-
induced pain hypersensitivity) occurred in non-dia-
betic mice under sufentanil (Figure  2, H2 to D3). OIH 
also occurred and was even enhanced in diabetic mice; 
we observed increased sufentanil-induced lowering of 
von Frey withdrawal threshold and thermal withdrawal 
latency in diabetic compared to the lowering in non-dia-
betic mice at D0 H4–6.
Regional anaesthesia with levobupivacaine was effi-
cient in preventing postoperative hyperalgesia and OIH 
in diabetic mice as well as in non-diabetic mice. This was 
demonstrated by the complete prevention of sufentanil-
lowered withdrawal threshold and shortened response 
latency during the D0–D4 period; the parameters were 
even significantly better than the control values with-
out sufentanil (Figures 2 and 3. This is the first evidence 
that RA can prevent OIH in diabetic models. In our 
study, perioperative regional anaesthesia was associated 
to high sufentanil (10 µg/kg). Previously, RA (long term 
ropivacaine sciatic nerve block) before plantar surgery 
reduced postoperative pain and long-term pain sen-
sitization in rat [39, 40]. However, the protective effect 
was lost when high doses of opioid (fentanyl) were used 
intraoperatively, showing that OIH was not impaired in 
rats.
The mechanism underlying OIH involves NMDA 
receptors [40, 41]. Increased NMDA activity also con-
tributes to central sensitization in neuropathic pain, 
including diabetic neuropathy [42–44]. The mechanisms 
may also involve mTOR signalling, important in diabetic 
complications [45], neuropathic pain [46] and morphine 
hyperalgesia [47]. Very recently, hyperalgesia induced by 
sufentanil, locally injected in paws, was prevented by an 
NMDA antagonist, in both diabetic and non-diabetic rats 
[48]. Here, RA was performed using levobupivacaine, a 
local anaesthetic, possibly acting also as NMDA antago-
nist [49–51]. Whether the impact of levobupivacaine on 
NMDA receptors could be involved in the prevention of 
OIH was not directly evaluated in the present study.
Wound healing of the incised paw, observed as sec-
ondary parameter, appeared improved by RA in the 
diabetic mice. RA has been reported to impact local 
inflammation and wound healing with either neu-
tral, negative or positive effects on healing in non-
diabetic animals [52]. Normal wound healing consists 
of haemostasis, inflammation, proliferative phase 
and fibrotic remodelling. In our study neutrophils 
infiltration and oedema were similar in diabetic and 
non-diabetic mice paws at D1 post-surgery. At D7, 
lymphocyte/plasmocytes/fibroblasts replaced neutro-
phils in non-diabetic mice whereas neutrophils were 
still present in diabetic mice. At D14, fibrosis (remod-
elling with fibroblasts) was observed in non-diabetic 
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Figure 4 Histology of mouse hindpaws. The effect of levobupivacaine and sufentanil were tested on histopathology of diabetic and non‑diabetic 
mouse hind paws at different days postsurgery: a non‑diabetic mice 1 day (D1) after skin incision showing acute inflammatory infiltration with poly‑
nuclear cells and oedema. b Non‑diabetic mice 7 days (D7) after skin incision showing myofibroblastic proliferation with some lymphocyte inflam‑
matory cells. c Non‑diabetic mice 14 days (D14) after skin incision showing wound healing of the conjunctive tissue with only few inflammatory 
cells and still fibroblastic superficial proliferation. d Non‑diabetic mice with RA at D14 showing wound healing of the conjunctive tissue with only 
few inflammatory cells and still fibroblastic superficial proliferation. e Diabetic mice at D1 showing acute inflammatory infiltration with polynuclear 
cells and oedema. f Diabetic mice at D7 showing persistent acute inflammatory cells and oedema. g Diabetic mice at D14 showing persistent acute 
inflammatory cells and oedema. h Diabetic mice with regional anaesthesia at D14 showing wound healing of the conjunctive tissue with only few 
inflammatory cells and still fibroblastic superficial proliferation.
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mice whereas an inflammatory state was still observed 
in diabetic mice paws. When RA was performed, no 
alteration was observed in non-diabetic mice at D14 
(remodelling) whereas remodelling was induced in dia-
betic mice. Bupivacaine has been reported to influence 
cutaneous wound inflammation (increased neutrophil 
numbers) in mice while healing (re-epithelialization) 
was not impaired [53]. In rats, levobupivacaine aug-
mented the fibrotic remodelling [54]. However, despite 
early beneficial effects, long time levobupivacaine 
impaired wound healing in rats [52]. Our preliminary 
histopathological observation is compatible with a 
positive impact of RA on healing in the diabetic ani-
mals (Figures 4, 5).
The present diabetic model exhibits clinical relevance, 
including diabetic neuropathy [9] and increased sciatic 
nerve block. In diabetic patients, sciatic block required 
lower doses [55] and subgluteal sciatic nerve block dura-
tion was increased in type 2 diabetes [56]. Anaesthetic 
and analgesic management of diabetic patients is still 
challenging. Clinical evidences show that regional anaes-
thesia might positively impact hyperalgesia and postsur-
gical pain [7]. OIH has been clearly evidenced in patients 
after surgery [14]; however the impact of diabetes on 
postoperative OIH has not yet been specifically studied 
in patients.
Conclusion
This study shows that regional anaesthesia can prevent 
opioid induced hyperalgesia in diabetic mice. These 
observations may be clinically relevant.
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